AUTHORS
Elena Zamagni, MD, PhD, Francesca Gay, MD, PhD2, Evangelos Terpos, MD3, Monica Galli, MD, PhD4, Eirini Katodritou, MD, PhD5, Barbara Gamberi, MD6, Angelo Belotti, MD7, Sara Aquino, MD, PhD8, Emmanouil Spanoudakis9, Irene Strassl, MD10, Marta Lombardo11, Andrea Crespo12, Anastasia Pouli, MD, PhD13, Martin Schreder, MD14, Massimo Offidani, MD15, Francesca Patriarca, MD, PhD16, Antonietta Pia Falcone17, Elisabetta Antonioli, MD18, Silvia Mangiacavalli, MD19, Gloria Margiotta Casaluci, MD20, Rachel Pearson21, Christopher Chiu22, Margaret Cobb23, Fatema Malbari24, Anna Sitthi-Amorn, MD25, Melissa Rowe, MD26, Mario Boccadoro, MD27, Pieter Sonneveld, MD, PhD28, Niels van de Donk, MD, PhD29
AFFILIATIONS
1 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
2 Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy, University of Torino, Tornio, Italy
3 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
5 Department of Hematology-Oncolgy, Theagenion Cancer Hospital, Thessaloniki, Greece
6 AUSL-IRCCS, Reggio Emilia, Italy
7 Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
8 Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy
9 Department of Hematology, University Hospital of Alexandroupolis, Alexandroupolis, Greece
10 Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Linz, Austria, Medical Faculty, Johannes Kepler University Linz, Linz, Austria
11 European Myeloma Network, Tornio, Italy
12 European Myeloma Network, Tornio, Italy
13 Department of Hematology, Agios Savvas Cancer Hospital, Athens, Greece
14 First Department of Medicine, Klinic Ottakring, Vienna, Austria
15 AOU delle Marche, Università Politecnica delle Marche, Ancona, Italy
16 Hematologic Clinic and Transplant Center, University Hospital of Central Friuli, DMED, University of Udine, Udine, Italy
17 Hematology, IRCCS 'Casa Sollievo della Sofferenza' Hospital, San Giovanni Rotondo, Italy
18 Hematology Unit, AOU Careggi, Florence, Italy
19 Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
20 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale/AOU Maggiore della Carità di Novara, Novara, Italy
21 Johnson & Johnson, Wycombe, United Kingdom
22 Johnson & Johnson, Raritan, New Jersey, United States
23 Johnson & Johnson, Wycombe, United Kingdom
24 Johnson & Johnson, Spring House, Pennsylvania, United States
25 Johnson & Johnson, Spring House, Pennsylvania, United States
26 Johnson & Johnson, Wycombe, United Kingdom
27 European Myeloma Network, Tornio, Italy
28 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands, European Myeloma Network, Tornio, Italy
29 Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
ABSTRACT
Introduction: Achievement of BM MRD negativity is associated with survival benefits. In the PERSEUS study, D-VRd induction/consolidation followed by D-R maintenance improved MRD-neg rates evaluated by next-generation sequencing (NGS) versus VRd followed by R maintenance in patients (pts) with TE NDMM. However, BM sampling for MRD testing is invasive, which may limit frequent sequential use in clinical practice. Here we present data from Cohort 1 of the phase 2, open-label, multi-cohort TAURUS study (NCT06189833), which is evaluating the agreement between PB-based mass spectrometry (MS)-MRD, standard BM NGS-MRD, and BM next-generation flow cytometry (NGF)-MRD following D-VRd induction/consolidation and autologous stem cell transplant (ASCT) in pts with TE NDMM.
Methods: Eligible pts had TE NDMM, were aged 18-70 yrs, and had an ECOG PS score ≤2. This analysis was limited to Cohort 1. Pts received six 28-day cycles (4 induction, ASCT, 2 consolidation) of modified D-VRd (D: 1800 mg SC QW Cycles 1-2, Q2W Cycles 3-6; V: 1.3 mg/m2 SC QW [Days 1/8/15/22]; R: 25 mg PO daily; d: 20 mg PO or IV Days 1/2/8/9/15/16/22/23). End of study was after Cycle 6. MRD assessments included NGS (Adaptive Biotechnologies) and NGF (Cytognos) in BM, and MS of M-protein in PB (2 assays: matrix-assisted laser desorption/ionization-time of flight [MALDI-TOF; TBS EXTENT® assay] and liquid chromatography-MS [LC-MS]). The primary endpoint—agreement of post-consolidation MRD by NGS (10–5) and MALDI-TOF—was assessed with a 1-sided exact binomial test (pre-specified α=0.05) to evaluate if agreement exceeded 75%.
Results: Cohort 1 included 175 pts. Median age was 60 (range 26-70) yrs. Myeloma subtypes were IgG (61.1%), IgA (18.9%), light chain (13.7%), biclonal (4.6%), and IgD (1.7%). Median treatment duration was 10.3 mos. Median follow-up was 11.2 mos. 92.0% of pts underwent ASCT.
At post-consolidation, agreement between NGS-MRD (10–5) and MALDI-TOF MS-MRD was high and statistically significant (82.4% [90% CI 76.1-87.7]; P=0.0277). Agreement was consistent across pre-specified clinically relevant subgroups. Across myeloma subtypes, post-consolidation agreement was highest for light-chain (94.1%) and decreased with longer isotype half-life (IgA/IgD, 86.7%; IgG, 78.2%), suggesting assessments after the post-consolidation timepoint may be required in future studies to achieve maximal agreement between MRD assays in subtypes with a longer half-life. Agreement for post-consolidation NGS-MRD (10–6) and MALDI-TOF MS-MRD was 70.6% (90% CI, 62.3-78.0); discordance was driven by NGS-pos/MALDI-TOF MS-neg samples. In sensitivity analyses, agreement between post-consolidation NGS-MRD (10–5) and LC-MS–MRD (more sensitive MS-MRD assay) was 62.6% (90% CI, 55.1-69.7) and between NGS-MRD (10–6) and LC-MS–MRD was 71.6% (90% CI, 63.3-78.9); discordance was driven mostly by NGS-neg/LC-MS–pos samples. For post-consolidation NGF, agreement was 77.0% (95% CI, 68.6-84.2) with MALDI-TOF MS-MRD and 87.2% (95% CI, 79.7-92.6) with NGS-MRD (10–5).
In MRD-evaluable pts, overall MRD-neg rates were 61.1% for NGS-MRD (10–5), 69.9% for NGF-MRD (10–5), 58.8% for MALDI-TOF MS-MRD, and 30.9% for NGS-MRD (10–6). Per investigator assessment, post-consolidation overall response rate was 93.1% and ≥CR rate was 49.1%.
The safety profile was generally consistent with the known profile of D-VRd induction/consolidation except any grade neuropathy occurred in only 17.1% of pts; this is lower than the 44% observed during induction in PERSEUS, which used twice-weekly bortezomib. Fatal adverse events occurred in 2 pts, both >30 days after the last study treatment.
Conclusions: In TAURUS Cohort 1, BM NGS-MRD (10–5) showed high and statistically significant agreement with PB MALDI-TOF MS-MRD. Lower agreement between BM NGS-MRD (10–5) and the more sensitive PB LC-MS–MRD assay may reflect slow M-protein clearance, particularly for isotypes with a longer half-life; data from Cohorts 2-4 with longer follow-up will help assess if the concordance increases over time. Despite weekly bortezomib dosing and ~50% lower dexamethasone exposure than PERSEUS, MRD-neg rates in TAURUS were generally consistent with post-consolidation rates in PERSEUS, supporting the efficacy of D-VRd with a less-intensive VRd regimen with lower peripheral neuropathy rate. These data support further evaluation of PB MS-based MRD monitoring in pts with TE NDMM and suggest PB-MRD is a promising alternative to more invasive BM techniques.
DISCLOSURES
Elena Zamagni, MD, PhD: Menarini Stemline - Honoraria; GSK - Honoraria; Janssen - Honoraria; Amgen - Honoraria; Oncopeptides - Honoraria; Sanofi - Honoraria; AstraZeneca - Honoraria; Pfizer - Honoraria; Roche - Honoraria; Bristol Myers Squibb - Honoraria; Sanofi - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony)